Riskpilot← Back to searchSign inGet full accessFEMINA GYN AS
ASActiveOrg 998079292Samvirkeveien 22, 1178 OsloMedical specialists activities · NACE 8622Est. 20121 employees
Revenue 2025
NOK 6,2M
+7% vs 2024
EBITDA margin
56.0%
+16% vs 2024
Equity ratio
0.6%
Financial strength
Net profit 2025
NOK 3,3M
+51% vs 2024
| Revenue | NOK 6,2M | +7% |
| EBITDA | NOK 3,5M | +16% |
| Net profit | NOK 3,3M | +51% |
| Total assets | NOK 4,8M | +16% |
| Equity | NOK 30K | -90% |
| Employees | 1 | — |
Legal name
FEMINA GYN AS
Org number
998079292
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
13. mars 2012
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Praksis og investeringer i kvinnehelserelatert virksomhet, samt alt som står i naturlig forbindelse med dette.
Address
Samvirkeveien 22, 1178 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4 820 | 5 023 | 5 557 | 5 743 | 6 171 |
| Staff expenses | −874 | −1 032 | −1 052 | −1 151 | −1 158 |
| EBITDA | 2 496 | 2 428 | 3 001 | 2 987 | 3 458 |
| Depreciation & amort. | −42 | −25 | −18 | −160 | −192 |
| EBIT | 2 454 | 2 403 | 2 983 | 2 827 | 3 267 |
| Net financials | −0 | −2 | 3 | 0 | 1 001 |
| Profit before tax | 2 454 | 2 401 | 2 986 | 2 828 | 4 267 |
| Tax | 537 | 523 | 622 | 622 | 939 |
| Net profit | 1 917 | 1 878 | 2 364 | 2 205 | 3 329 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 725 | 2 732 | 3 990 | 4 140 | 4 819 |
| Equity | 30 | 30 | 924 | 299 | 30 |
| Long-term debt | 0 | 0 | 33 | 13 | 80 |
| Short-term debt | 2 695 | 2 702 | 3 034 | 3 827 | 4 709 |
| Total debt | 2 695 | 2 702 | 3 067 | 3 841 | 4 789 |
EBITDA margin
56.0%
This company
15.8%
Market median
+254% vs market
20212025
Equity ratio
0.6%
This company
38.2%
Market median
-98% vs market
20212025
Return on equity
11095.1%
This company
18.4%
Market median
+60199% vs market
20212025
Net profit margin
53.9%
This company
8.1%
Market median
+565% vs market
20212025
Asset turnover
1.28×
This company
1.12×
Market median
+14% vs market
20212025
Debt / equity
159.63×
This company
0.62×
Market median
-25647% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HH Deputy Member | Deputy Member | 2012 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2012 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Åmu Invest As
FEMINA GYN AS Board members of FEMINA GYN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Håvard Holth Mundal | Deputy Member | 0 companies |
| Åsle Marit Ullern | Chairman | 0 companies |